359 related articles for article (PubMed ID: 30412106)
1. Immune checkpoint inhibitors of CTLA4 and PD-1 for malignant melanoma arising in ovarian cystic teratoma: A case report.
Yano M; Asami Y; Nishikawa T; Yoshida S; Kamada K; Katoh T; Teramoto Y; Nakamura Y; Yasuda M
Medicine (Baltimore); 2018 Oct; 97(43):e12937. PubMed ID: 30412106
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report.
Lepir T; Zaghouani M; Roche SP; Li YY; Suarez M; Irias MJ; Savaraj N
Medicine (Baltimore); 2019 Jan; 98(2):e13804. PubMed ID: 30633154
[TBL] [Abstract][Full Text] [Related]
3. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
4. Primary Ovarian Melanoma Arising From a Mature Teratoma With Melanoma In Situ Present in the Ciliated Columnar and Squamous Epithelium in a Patient With Synchronous Skin Basal Cell Carcinoma.
Lai J; Garvey KY; Li P; Azevedo RA
Int J Gynecol Pathol; 2021 Jul; 40(4):383-390. PubMed ID: 33560745
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z
Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
8. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
9. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
Carlino MS; Long GV; Schadendorf D; Robert C; Ribas A; Richtig E; Nyakas M; Caglevic C; Tarhini A; Blank C; Hoeller C; Bar-Sela G; Barrow C; Wolter P; Zhou H; Emancipator K; Jensen EH; Ebbinghaus S; Ibrahim N; Daud A
Eur J Cancer; 2018 Sep; 101():236-243. PubMed ID: 30096704
[TBL] [Abstract][Full Text] [Related]
10. Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition.
Friedman CF; Postow MA
Curr Oncol Rep; 2016 Apr; 18(4):21. PubMed ID: 26922327
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint blockade.
Naidoo J; Page DB; Wolchok JD
Hematol Oncol Clin North Am; 2014 Jun; 28(3):585-600. PubMed ID: 24880949
[TBL] [Abstract][Full Text] [Related]
12. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
13. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
15. Primary malignant melanoma in cystic teratoma of ovary.
Suneja A; Yadav P; Sharma A; Vaid NB; Singh B; Grover RK
Indian J Cancer; 2009; 46(4):340-2. PubMed ID: 19749467
[No Abstract] [Full Text] [Related]
16. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.
Blake Z; Marks DK; Gartrell RD; Hart T; Horton P; Cheng SK; Taback B; Horst BA; Saenger YM
J Immunother Cancer; 2018 Apr; 6(1):25. PubMed ID: 29622046
[TBL] [Abstract][Full Text] [Related]
17. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
18. Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.
Spain L; Larkin J
Immunotherapy; 2016 Jun; 8(6):677-9. PubMed ID: 27197536
[No Abstract] [Full Text] [Related]
19. Amelanotic malignant melanoma arising in an ovarian cystic teratoma: a case report.
Watanabe Y; Ueda H; Nakajima H; Minoura R; Hoshiai H; Noda K
Acta Cytol; 2001; 45(5):756-60. PubMed ID: 11575655
[TBL] [Abstract][Full Text] [Related]
20. Malignant melanoma involving the ovary: a clinicopathologic and immunohistochemical study of 23 cases.
Gupta D; Deavers MT; Silva EG; Malpica A
Am J Surg Pathol; 2004 Jun; 28(6):771-80. PubMed ID: 15166669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
